Analytical and biological validation of a multiplex immunoassay for acute kidney injury biomarkers

Clinica Chimica Acta

Volumn 415, Issue , 2013, Pages 88-93

  Zhang, Xiaochun ^a   Gibson, Bill ^a   Mori, Ryan ^a   Snow Lisy, Devon ^a   Yamaguchi, Yuka ^a   Campbell, Steven C ^a   Simmons, Matthew N ^a   Daly, Thomas M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute kidney injury; Cystatin C; Interleukin 18; Kidney injury molecule 1; Multiplex assay; Neutrophil gelatinase associated lipocalin

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ACCURACY; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ACTIVITY; ELECTROIMMUNOASSAY; HUMAN; INSTRUMENT VALIDATION; LIMIT OF QUANTITATION; NORMAL HUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; URINALYSIS;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CALIBRATION; CASE-CONTROL STUDIES; CYSTATIN C; FEMALE; HUMANS; IMMUNOASSAY; INTERLEUKIN-18; LIPOCALINS; LUMINESCENCE; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OBSERVER VARIATION; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84868261485     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.09.022     Document Type: Article

References (33)

1. Tesch G.H. Review: serum and urine biomarkers of kidney disease: a pathophysiological perspective. Nephrology (Carlton) 2010, 15:609-616.
2. Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212. Acute Dialysis Quality Initiative w.
3. Molitoris B.A., Levin A., Warnock D.G., et al. Improving outcomes of acute kidney injury: report of an initiative. Nat Clin Pract Nephrol 2007, 3:439-442.
4. Ferguson M.A., Waikar S.S. Established and emerging markers of kidney function. Clin Chem 2012, 58:680-689.
5. Siew E.D., Ware L.B., Ikizler T.A. Biological markers of acute kidney injury. J Am Soc Nephrol 2011, 22:810-820.
6. Krawczeski C.D., Goldstein S.L., Woo J.G., et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol 2011, 58:2301-2309.
7. Slocum J.L., Heung M., Pennathur S. Marking renal injury: can we move beyond serum creatinine?. Transl Res 2012, 159:277-289.
8. Hlatky M.A., Greenland P., Arnett D.K., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416.
9. Al-Ismaili Z., Palijan A., Zappitelli M. Biomarkers of acute kidney injury in children: discovery, evaluation, and clinical application. Pediatr Nephrol 2011, 26:29-40.
10. Koyner J.L., Bennett M.R., Worcester E.M., et al. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int 2008, 74:1059-1069.
11. Parikh C.R., Devarajan P. New biomarkers of acute kidney injury. Crit Care Med 2008, 36:S159-S165.
12. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238.
13. Parikh C.R., Jani A., Melnikov V.Y., Faubel S., Edelstein C.L. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004, 43:405-414.
14. Ichimura T., Bonventre J.V., Bailly V., et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998, 273:4135-4142.
15. van Timmeren M.M., van den Heuvel M.C., Bailly V., Bakker S.J., van Goor H., Stegeman C.A. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007, 212:209-217.
16. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioanalytical method validation (ucm070107) Accessed Aug 22, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/uc.
17. Minchinela J, Ricos C., Perich C, et al. Biological variation database, and quality specifications for imprecision, bias and total error (desirable and minimum). The 2012 update [Accessed August 15, 2012]. http://westgard.com/biodatabase1.htm.
18. Liangos O., Addabbo F., Tighiouart H., Goligorsky M., Jaber B.L. Exploration of disease mechanism in acute kidney injury using a multiplex bead array assay: a nested case-control pilot study. Biomarkers 2010, 15:436-445.
19. Doi K., Negishi K., Ishizu T., et al. Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med 2011, 39:2464-2469.
20. Koyner J.L., Vaidya V.S., Bennett M.R., et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 2010, 5:2154-2165.
21. Petersen P.H., Fraser C.G., Jorgensen L., et al. Combination of analytical quality specifications based on biological within- and between-subject variation. Ann Clin Biochem 2002, 39:543-550.
22. Grenier F.C., Ali S., Syed H., et al. Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability. Clin Biochem 2010, 43:615-620.
23. Delanaye P., Rozet E., Krzesinski J.M., Cavalier E. Urinary NGAL measurement: biological variation and ratio to creatinine. Clin Chim Acta 2011, 412:390.
24. Cullen M.R., Murray P.T., Fitzgibbon M.C. Establishment of a reference interval for urinary neutrophil gelatinase-associated lipocalin. Ann Clin Biochem 2012, 49:190-193.
25. Herget-Rosenthal S., Feldkamp T., Volbracht L., Kribben A. Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range. Ann Clin Biochem 2004, 41:111-118.
26. Conti M., Moutereau S., Zater M., et al. Urinary cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med 2006, 44:288-291.
27. Uchida K., Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta 2002, 323:121-128.
28. Ralib A.M., Pickering J.W., Shaw G.M., et al. Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury. J Am Soc Nephrol 2012, 23:322-333.
29. Nickolas T.L., Schmidt-Ott K.M., Canetta P., et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol 2012, 59:246-255.
30. Ricos C., Iglesias N., Garcia-Lario J.V., et al. Within-subject biological variation in disease: collated data and clinical consequences. Ann Clin Biochem 2007, 44:343-352.
31. Waikar S.S., Sabbisetti V.S., Bonventre J.V. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int 2010, 78:486-494.
32. Fraser C.G. Biological variation: from principles to practice 2001, AACC Press, Washington, DC. 1st ed.
33. Fraser C.G. Improved monitoring of differences in serial laboratory results. Clin Chem 2011, 57:1635-1637.